Dr. Reddy's Laboratories Limited has received a letter dated March 5, 2026, from the U.S. Department of Justice, Criminal Division, Fraud Section, stating that the Department has closed its inquiry under the Foreign Corrupt Practices Act (FCPA). Based on the information available to it, the Department has not recommended any enforcement action against the Company. This announcement follows a previous intimation on February 24, 2026, where the Company informed that it had received a letter from the U.S. Securities and Exchange Commission (SEC) dated February 23, 2026. The SEC had concluded its investigation into allegations of improper payments to healthcare professionals in Ukraine and potentially other countries and did not intend to recommend any enforcement action against the Company at that time. The Company had initially commenced a detailed investigation into an anonymous complaint regarding these allegations, which could constitute violations of U.S. anti-corruption laws, including the FCPA. This matter was disclosed to the U.S. Department of Justice (DOJ), the U.S. Securities and Exchange Commission (SEC), and the Securities Exchange Board of India (SEBI). A U.S. law firm was engaged to conduct the investigation at the directions of the Company's Board of Directors.
